Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Sinan Mersin, Fatih Gülük, Emirhan Gülcan & Ahmet Emre Eşkazan. (2023) Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults. Expert Opinion on Pharmacotherapy 24:15, pages 1703-1713.
Read now
Read now
Bee Kim Tan, Ping Chong Bee, Siew Siang Chua & Li-Chia Chen. (2021) Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review. Patient Preference and Adherence 15, pages 2563-2575.
Read now
Read now
Fiorenzo Santoleri, Elena Ranucci, Gaetano La Barba, Irene Colasanto, Matilde Scaldaferri, Francesco Cattel, Francesca Federici, Chiara Rossi, Katiuscia Di Biagio, Anna Rita Scortechini, Felice Musicco, Giancarlo Torquati, Angela Frazzetto, Antonietta Vozza, Caterina de Rosa, Rosaria Lanzillo, Maria Monteverde, Luigia Luciano, Fabrizio Pane, Arianna Pasquazi, Maria Grazia Celeste, Maria Cantonetti, Luca Franceschini, Manuela Rizzo & Alberto Costantini. (2021) Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life. Current Medical Research and Opinion 37:3, pages 477-481.
Read now
Read now
Federico De Marchi, Marta Medeot, Renato Fanin & Mario Tiribelli. (2017) How could patient reported outcomes improve patient management in chronic myeloid leukemia?. Expert Review of Hematology 10:1, pages 9-14.
Read now
Read now
B. Douglas Smith, Jun Liu, Dominick Latremouille-Viau, Annie Guerin, Daniel Fernandez & Lei Chen. (2016) Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy. Current Medical Research and Opinion 32:5, pages 817-827.
Read now
Read now
Meri Kekäle, Marikki Peltoniemi & Marja Airaksinen. (2015) Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Preference and Adherence 9, pages 1733-1740.
Read now
Read now
Annie Guérin, Lei Chen, Eric Q. Wu, Diego Ponce de Leon & James D. Griffin. (2012) A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Current Medical Research and Opinion 28:7, pages 1155-1162.
Read now
Read now
Eric Wu & Lei Chen. (2012) Letter to the editor. Current Medical Research and Opinion 28:7, pages 1163-1165.
Read now
Read now
Articles from other publishers (22)
Samantha E. Clark, Zachary A. Marcum, Jerry Radich, Ruth Etzioni & Anirban Basu. (2023) Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients. Journal of Oncology Pharmacy Practice.
Crossref
Crossref
Karen B. Farris, Tiffany Cadwallader, Joel Farley, Katie Gatwood, Emily Mackler & Justin Gatwood. (2022) Implementation of a model integrating primary and oncology pharmacists' care for patients taking oral anticancer agents (OAA). Exploratory Research in Clinical and Social Pharmacy 7, pages 100163.
Crossref
Crossref
Yundeok Kim, Tae-Hwa Go, Jaeyeon Jang, Jii Bum Lee, Seung Taek Lim, Kwang Yong Shim, Jong In Lee & Jee Hyun Kong. (2021) Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia. The Korean Journal of Internal Medicine 36:6, pages 1450-1458.
Crossref
Crossref
Sue P. Heiney, McKenzie Sorrell, Jingxi Sheng, Swann A. Adams, Kathy Nelson, Lan A. Nguyen, Amy Edwards & Karen E. Wickersham. (2021) Interventions to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. American Journal of Clinical Oncology Publish Ahead of Print.
Crossref
Crossref
Michael W. DeiningerNeil P. ShahJessica K. AltmanEllin BermanRavi BhatiaBhavana BhatnagarDaniel J. DeAngeloJason GotlibGabriela HobbsLori ManessMonica MeadLeland MethenySanjay MohanJoseph O. MooreKiran NaqviVivian OehlerArnel M. PalleraMrinal PatnaikKeith PratzIskra PusicMichal G. RoseB. Douglas SmithDavid S. SnyderKendra L. SweetMoshe TalpazJames ThompsonDavid T. Yang, Kristina M. Gregory & Hema Sundar. (2020) Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 18:10, pages 1385-1415.
Crossref
Crossref
Christel C. L. M. Boons, Lonneke Timmers, Jeroen J. W. M. Janssen, Peter E. Westerweel, Nicole M. A. Blijlevens, Willem M. Smit, Imke H. Bartelink, Janneke A. Wilschut, Eleonora L. Swart, N. Harry Hendrikse & Jacqueline G. Hugtenburg. (2020) Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib. European Journal of Clinical Pharmacology 76:9, pages 1213-1226.
Crossref
Crossref
Ankur A. Dashputre, Katie S. Gatwood & Justin Gatwood. (2020) Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of Managed Care & Specialty Pharmacy 26:2, pages 186-196.
Crossref
Crossref
Takuya IwamotoFumihiko MonmaKohshi OhishiAkira UminoKei SuzukiKoji OkaKeiki Kawakami, Takao SekineMasahiro OkudaNaoyuki Katayama. (2019) Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study. Therapeutic Drug Monitoring 41:5, pages 575-581.
Crossref
Crossref
Mariana M. Fachi, Fernanda S. Tonin, Leticia P. Leonart, Karina S. Aguiar, Luana Lenzi, Bonald C. Figueiredo, Fernando Fernandez-Llimos & Roberto Pontarolo. (2018) Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis. European Journal of Cancer 104, pages 9-20.
Crossref
Crossref
Jochen Hefner, Eva-Johanna Csef & Volker Kunzmann. (2017) Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors. Oncology Nursing Forum 44:6, pages E232-E240.
Crossref
Crossref
Tomasz Sacha, Joanna Góra-Tybor, Ewa Wąsak-Szulkowska, Sławomira Kyrcz-Krzemień, Ewa Mędraś, Rafał Becht, Grażyna Bober, Aneta Kotowska, Joanna Wącław & Andrzej Hellmann. (2017) Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study. Clinical Lymphoma Myeloma and Leukemia 17:5, pages 283-295.
Crossref
Crossref
Wai Mun Sean Leong & Chen Wee Derrick Aw. (2016) Nilotinib-Induced Keratosis Pilaris. Case Reports in Dermatology 8:1, pages 91-96.
Crossref
Crossref
Alix E. Hall, Chris Paul, Jamie Bryant, Marita C. Lynagh, Philip Rowlings, Anoop Enjeti & Hannah Small. (2016) To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients. Critical Reviews in Oncology/Hematology 97, pages 247-262.
Crossref
Crossref
Marie Barillet, Virginie Prevost, Florence Joly & Bénédicte Clarisse. (2015) Oral antineoplastic agents: how do we care about adherence?. British Journal of Clinical Pharmacology 80:6, pages 1289-1302.
Crossref
Crossref
Lei Chen & Eric Q. Wu. (2015) Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment. Journal of Managed Care & Specialty Pharmacy 21:11, pages 1088-1089.
Crossref
Crossref
Nicholas J. Di Bella, Debajyoti Bhowmik, Menaka Bhor, Mark Yap, Brooke Middlebrook, Debra Rembert, Zachary Cain, Tony Okoro, Bjorn Bolinder, Debra Patt & Elias J. Jabbour. (2015) The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting. Clinical Lymphoma Myeloma and Leukemia 15:10, pages 599-605.
Crossref
Crossref
Henry J. Henk, Mabel Woloj, Mark Shapiro & Jennifer Whiteley. (2015) Real-world Analysis of Tyrosine Kinase Inhibitor Treatment Patterns Among Patients With Chronic Myeloid Leukemia in the United States. Clinical Therapeutics 37:1, pages 124-133.
Crossref
Crossref
Maria Helena de Almeida, Laura Fogliatto & Dulce Couto. (2014) Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia. Revista Brasileira de Hematologia e Hemoterapia 36:1, pages 54-59.
Crossref
Crossref
David Cella, Cindy J. Nowinski & Olga Frankfurt. (2014) The Impact of Symptom Burden on Patient Quality of Life in Chronic Myeloid Leukemia. Oncology 87:3, pages 133-147.
Crossref
Crossref
Anand C. Patel. (2013) Clinical Relevance of Target Identity and Biology: Implications for Drug Discovery and Development. SLAS Discovery 18:10, pages 1164-1185.
Crossref
Crossref
Cheryl-Anne Simoneau. (2013) Treating Chronic Myeloid Leukemia. Clinical Journal of Oncology Nursing 17:1, pages E13-E20.
Crossref
Crossref
Massimo Breccia, Fabio Efficace & Giuliana Alimena. (2012) Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Leukemia Research 36:7, pages 804-805.
Crossref
Crossref